Company intelligence / Profile preview
LUCA AICell
Anyang, Gyeonggi-do, South Korealucaaicell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LUCA AICell has developed a proprietary lipid bilayer platform enabling broad-spectrum antiviral therapies, drug delivery for mRNA and gene therapies, cancer/virus diagnostics, and gene delivery. Their work is in the preclinical stage, with ongoing collaborations and technology partnerships, but no public clinical trial results yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Lipid nanoparticle delivery therapySmall moleculeAntiviral peptideGene deliveryAntibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ABITEC CorporationLarodanNTU SingaporeSNU HospitalCHA BiotechUNISTHongik UniversityStanford UniversityHarvard UniversityUCLAUtrecht UniversityTwenteGhent UniversityONOM MongoliaUFMG Brazil
Beyond the preview
Go deeper on LUCA AICell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUCA AICell.